Research on cancer as a disease, from cause to care. Covers tumor biology, small-cell lung cancer, cancer-linked stroke risk, and cancer center research.
Researchers have established that Candida albicans fungus makes melanoma more aggressive by activating signaling pathways and creating conditions for malignant cells to acquire oxygen and energy. The study's findings suggest potential new avenues for cancer treatment using antifungal therapies.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center developed a new zinc oxide formulation that significantly reduces the white, chalky cast associated with traditional mineral sunscreens. The tetrapod-shaped particles provide strong protection against UV radiation while staying evenly distributed in the sunscreen.
George Coukos directs the Ludwig Laboratory for Cell Therapy at Weill Cornell Medicine's Sandra and Edward Meyer Cancer Center. The lab focuses on developing personalized cellular immunotherapies to optimize cancer treatment strategies.
A new study suggests that women vaccinated against human papillomavirus (HPV) may only need cervical cancer screenings 2-3 times over a lifetime, without compromising health benefits. This approach could lead to cost-effectiveness and reduced unnecessary follow-up procedures.
Researchers at Johns Hopkins Kimmel Cancer Center have developed a novel liquid biopsy approach to identify early-stage cancers by measuring DNA methylation patterns. The Epigenetic Instability Index (EII) successfully distinguished patients with early-stage lung and breast cancers from healthy individuals, showing promise in detecting...
Researchers developed polygenic risk score models to predict breast cancer risk in women of African ancestry, improving accuracy and performance compared to existing models. The new tools could lead to earlier screening, tailored care, and increased survival rates for high-risk women.
Researchers created a miniaturized ultrasound system that can be used at home or in doctors' offices to scan people at high risk of breast cancer. The new system detects tumors earlier, increasing the chances of successful treatment.
Key cytokines in tumor microenvironment exhibit both protumor and antitumor effects, influencing immune response and tumor progression. Current research focuses on reducing toxicity while enhancing efficacy of cytokine therapies.
Vinay Badhwar, MD, was elected President of The Society of Thoracic Surgeons with a three-part framework emphasizing daily practice excellence, data-driven science, and measurable impact. He aims to advance collaboration across surgical disciplines and integrate the specialty into the broader healthcare ecosystem.
Breakthrough research recommends that more than one N1 node be removed and evaluated during surgery for non-small cell lung cancer (NSCLC). The study found that many cancers were identified in N1 nodes adjacent to the bronchi, highlighting the need for expanded lymph node evaluation.
A review decodes the comprehensive role of GDF15 in prostate cancer metabolism, chemoresistance, and clinical applications, highlighting its involvement in cachexia, bone metastasis, and drug resistance. The study also explores the synergistic power of combining GDF15 with established markers for improved diagnosis and prognosis.
Researchers identified a crucial factor that may help improve treatment for glioblastoma, one of the most aggressive and common forms of adult brain cancer. They discovered a small molecule called miR-181d acts like a master switch that controls how much MGMT is produced by each glioblastoma cell.
Biologist Douglas Hanahan proposes an updated framework to help understand the complexity of human cancer. The new framework, known as Hallmarks of Cancer, offers a four-dimensional approach to analyzing cancer development and progression.
A new clinical trial shows that treating desmoplastic melanoma with immunotherapy before surgery dramatically shrinks or eliminates tumors, improving quality of life for patients. The study found that 71% of patients had no detectable cancer remaining at the time of surgery.
Researchers have developed a four-marker panel that can detect early-stage pancreatic cancer with high accuracy, potentially improving survival rates. The new test distinguishes cancer patients from healthy individuals and those with non-cancerous conditions, such as pancreatitis.
A cross-sectional analysis of nationwide population data reveals that high-deductible health plans are associated with worse overall and cancer-specific survival among cancer survivors. The study suggests that financial disincentives for medical care may lead to delayed or foregone necessary care, ultimately worsening cancer outcomes.
Researchers found that certain gut bacteria can deplete amino acids, affecting tumor growth or activating immune cells. Tailoring diets and microbiome strategies may enhance anti-tumor activity and support personalized therapy.
A recent study found that low-dose aspirin use was not associated with incident cancer incidence in older adults, contrary to previous findings. However, the study revealed a significant elevation in cancer mortality risk during the randomized clinical trial period, which did not persist after the trial ended.
Researchers developed a new framework called SOLVE to overcome data challenges in precision cancer treatment. By jointly modeling known and unknown factors, SOLVE provides a robust tool for biomarker discovery and investigating tumor responses.
A study led by researchers from the Germans Trias i Pujol Research Institute has identified PARG as a new target to enhance chemotherapy in colorectal cancer. Inhibition of PARG significantly increases the cytotoxic effect of chemotherapy, leading to enhanced cell death and apoptosis in different colorectal cancer models.
Researchers identified statins as a potential booster for cancer immunotherapy by preventing the release of PD-L1-containing sEVs. Statin treatment suppressed UBL3 modification, reduced PD-L1 sorting into sEVs, and improved survival outcomes in lung cancer patients.
Researchers developed miniature 3D tumor organoid models that closely mimic the human brain, revealing how glioblastoma interacts with surrounding brain cells and immune system. The models identified PTPRZ1 as a key regulator of tumor behavior, which helps determine its aggressiveness.
Cancer cells tap into the nervous system's power grid by forming synaptic contacts with nerve cells, promoting tumor growth and spread. Venkataramani's research aims to repurpose the drug perampanel for glioblastoma treatment and develop gene therapy approaches to disconnect tumors from the nervous system.
Researchers at Brown University discovered that the shape of spheroid aggregates influences cell behavior, with cells invading outward from sharper ends. The study used fluorescent proteins to track cell movement and measured forces exerted by cells as they move.
A new AI-powered model predicts patient survival and risk stratification for spinal metastasis, allowing for more informed treatment decisions. The model achieved high predictive accuracy using large-scale clinical data from Japanese patients.
Researchers at UC San Francisco found that spindle fibers can repair themselves as they pull on DNA, ensuring accurate chromosome division. This self-repair mechanism replaces weak links with stronger ones, preventing errors that could lead to cancer or birth defects.
Researchers developed a novel way to identify aggressive cancer cells by observing how they physically interact with their environment. The new technology uses specially designed microscopic surfaces to distinguish between aggressive and less aggressive cells.
Researchers at Tohoku University designed optimized solvents that improve drug delivery to metastatic lymph nodes, promoting blood flow and expanding the lymphatic sinus as a drug pathway. These findings support the clinical application of Lymphatic Drug Delivery Systems (LDDS) in cancer treatment.
This review analyzes molecular mechanisms of DDR pathways in mediating chemotherapy resistance, elucidating correlations with BRCA1/2 deficiency and ATM/ATR signaling pathway dysregulation. The study presents a novel molecular synergy model between DDR regulation and Immune Checkpoint Blockade to enhance immunotherapy responses.
A real-world study compared LLMs to human physicians in challenging lung cancer cases, finding that LLMs excel in rare cases with high comprehensiveness and specificity scores. However, they struggle with refractory cases, where physicians' reasoning stability is crucial.
Researchers found that circadian regulation shapes tumor microenvironment and determines patient responses to immune checkpoint blockade therapies. Disrupting these rhythms can suppress immune responses and diminish treatment efficacy.
Researchers summarize the role of metabolic reprogramming in driving prostate cancer progression, highlighting key regulators and inter-pathway crosstalk mechanisms. Novel targeted therapeutic strategies targeting glucose, glutamine, and lipid metabolism are proposed to overcome current treatment bottlenecks.
The study reveals that orphan non-coding RNAs (oncRNAs) exist across all major cancer types and can be used as digital molecular barcodes to capture cancer cell identity. The research also identifies oncRNAs that drive cancer progression, with some showing promise as biomarkers for monitoring patients.
A study by Stanford Medicine researchers found that people with colorblindness have a 52% higher mortality rate over 20 years compared to those with normal vision due to delayed diagnosis. The study suggests that missing the early sign of blood in urine can lead to worse outcomes.
Researchers developed bioengineered lymphatic tissue (CeLyT) that restored functional lymph nodes in mice with secondary lymphedema. CeLyTs improved lymphedema symptoms by restoring lymphatic flow, filtration capacity, and immune cell populations.
Smoking exposure induces tumor microenvironment promoting sorafenib resistance in HCC by modifying the 14-3-3η proteome. Arsenic trioxide suppresses tumor progression with synergistic effect when combined with sorafenib.
The report shows a notable increase in medication treatments, such as chemotherapy, immunotherapy, and hormone therapy, used before surgery to treat many cancers. Neoadjuvant systemic therapy increased notably for certain cancers, including gynecologic cancers, pancreatic cancer, and rarer abdominal lining cancers.
Scientists at UNIGE created an AI tool called MangroveGS that can accurately predict the risk of cancer metastasis and recurrence. The algorithm uses gene expression signatures from colon cancer cells to identify key factors influencing metastatic potential, paving the way for more precise care and discovery of new therapeutic targets.
A study published by the National Institutes for Quantum Science and Technology found that carbon-ion radiotherapy provided durable tumor control with minimal side effects while preserving breast appearance in carefully selected patients who were unable or unwilling to undergo surgery. The treatment resulted in excellent local control ...
Cancer mortality rates have decreased for breast cancer and leukemia, despite increasing incidence, while colorectal cancer has become the leading cause of death among US young adults. Colorectal cancer surpasses lung, breast, and prostate cancers as the leading cancer-related death in people under 50 years old.
The event highlighted urgent global risks and science-led solutions for antimicrobial resistance, trust in data, and AI-enabled sustainable cities. Experts emphasized the need for immediate actions against AMR, which could kill more people than cancer by 2050.
The Ralph Lauren Corporate Foundation has awarded a grant to establish the UChicago Medicine Ralph Lauren Center, expanding access to high-quality cancer screening and care in Chicago's South Side. The new center will focus on personalized and comprehensive approaches to patient navigation and prevention services.
Scientists at Northwestern University have determined the three-dimensional structures of rye pollen's cancer-fighting molecules, secalosides A and B. This breakthrough opens the door to exploring how these molecules interact with the immune system and could inspire new approaches to cancer therapy.
SPARK Microgravity plans to build Europe's first dedicated commercial orbital cancer lab, allowing researchers to run experiments impossible on Earth. This will accelerate the path from discovery to therapy, with microgravity enabling 3D tumor growth and revealing new drug targets.
Researchers found that obesity and estrogen-based medications synergistically increase thrombotic risk by suppressing Protein S levels. This study offers new insights for cancer care, highlighting the need to monitor and prevent blood clots in patients with obesity or estrogen use.
Researchers found that Fusobacterium nucleatum accelerates tumor growth and increases cancer cell spread in animal models of human breast cancer, particularly in cells with BRCA1 gene mutations. The study reveals a connection between oral microbes and breast cancer risk and progression.
Dr. Brian Leyland-Jones was a renowned breast cancer oncologist and translational research leader who played a pivotal role in advancing cancer therapies. He made himself available to patients in need, offering his expertise pro bono and guiding them through diagnoses and treatment options.
A national clinical trial found that abemaciclib, an oral cancer drug, may slow tumor growth in patients with aggressive meningiomas with specific genetic mutations. The trial showed promising results, with a median progression-free survival of 10 months and a median overall survival of 29 months.
Researchers at Penn Vet have shown that trained dogs can identify the odor of hemangiosarcoma, a malignant cancer of blood vessel cells, with an accuracy rate of 70%. Early detection could lead to better outcomes, including prevention of disease spread and earlier removal of the spleen or initiation of chemotherapy.
A new review proposes a two-stage model explaining how different determinants of aging interact to generate late-life disease. Early-life damage and late-life genetic activity are identified as key drivers of age-related illnesses.
A new blood test has identified a protein signature linked to cancer in patients with non-specific symptoms. The test distinguishes cancer from other conditions with high precision and can help prioritize patients for further diagnostics.
A new study found that nearly half of Medicare Part D beneficiaries with cancer face high out-of-pocket prescription drug costs, often leading to delayed treatment initiation and poorer health outcomes. Enrolling in the Medicare Prescription Payment Plan (M3P) could reduce monthly payment volatility and mitigate cost-related nonadherence.
Predictions for lung cancer death rates among EU and UK women indicate stabilization of mortality rates at 12.5 deaths per 100,000 in 2026. Lung cancer remains the leading cause of cancer death for both sexes in the EU, with mortality rates continuing to decline among men.
Researchers developed a highly sensitive blood test that can detect initial thrombin generation, a key trigger in blood clot formation. The test distinguishes between pathway-specific clotting abnormalities and suggests personalized treatment strategies, potentially predicting clinical outcomes.
A Purdue-developed mRNA therapy delivery system has shown promise in targeting bladder cancer cells with improved efficiency. The system, called LENN, can be freeze-dried and stored for several days without losing its biological activity.
The Phase 2 ANDROMEDA trial combines two types of PSMA-targeted radiopharmaceuticals with stereotactic body radiotherapy to delay progression and minimize side effects in patients with oligorecurrent prostate cancer. Researchers aim to determine which approach provides the most durable cancer control.
Researchers summarize itaconate biology highlighting its chemical reactivity and therapeutic potential in treating infectious diseases, sepsis, autoimmunity, neurodegenerative disorders. Itaconate exerts biological effects through post-translational modifications, altering protein activity and signaling pathways
A research team at Goethe University Frankfurt has compiled a catalog of human E3 ligases and mapped their relationships, revealing family-specific functions. The study identifies 40 additional E3 ligases suitable for PROTAC development, expanding the range of tissues and diseases targeted by degradation therapies.
Researchers have created a library of over 400 immune-related factors to reprogram rare immune cell populations. This technique allows for the systematic discovery of 'recipes' for specific immune cells, offering hope for unresponsive patients and advancing immunotherapy.
Researchers at the University of Florida have discovered a small compound produced by gut bacteria that doubles the response to lung cancer immunotherapy treatment in mice. The findings could lead to a new combination therapy that boosts patient responsiveness by 50% without adding invasive treatments.